Evels of calcium [8]. On the other hand, its effect upon cardiovascular calcification, cardiovascular mortality, all-cause mortality and hospitalization is not known. Various reviews [93] have focused on sevelamer, one of which was conducted in 2010 involving 14 trials and 3271 patients [9]. In that meta-analysis, the authors included predialysis sufferers and evaluated the level of cardiovascular calcification making use of coronary artery calcification scores (CACS), graded by computed tomography (CT) and representing the progression or regression of coronary artery illness, [14, 15] in 4 randomized controlled trials (RCTs) in hemodialysis patients. Jamal et al. (2009) [10] also analyzed cardiovascular calcification by CACS, but located no substantial variations in CACS in between patient groups and controls. 3 of those reviews [113] regarded biochemical outcomes, and a single assessment also evaluated the impact of sevelamer upon all-cause mortality, cardiovascular events, as well as other adverse events [11]. Considering that then, various trials connected to this problem have been published. It seems that an updated review of the evidence could be of good use to clinicians and decision-makers. Hence, we carried out a meta-analysis of published RCTs around the effectiveness and safety of sevelamer in dialysis sufferers.Supplies and Strategies Information Sources and Literature SearchesWe undertook a systematic meta-analysis of RCTs as outlined by Preferred Reporting Things for Systematic Testimonials and Meta-analyses (PRISMA) guidelines (S1 Fig) [16]. We conducted a MEDLINE literature search to identify all relevant studies using the search terms `sevelamer hydrochloride’, `sevelamer’, or `RenaGel’ from January 1998 to November 2013 and searched PUBMED, EMBASE (`sevelamer hydrochloride’/exp OR `sevelamer hydrochloride’ ORPLOS One | DOI:10.1371/journal.pone.0133938 July 31,two /A Meta-Analysis of Sevelamer on DialysisFig 1. Flow diagram of studies regarded as for inclusion. doi:10.1371/journal.pone.0133938.g`sevelamer’/exp OR sevelamer AND (`renagel’/exp OR renagel) 1811), the specialized register on the Cochrane Renal Group, along with the Cochrane Central Register of Controlled Trials to recognize all RCTs studying the effects of sevelamer hydrochloride applying equivalent search terms. We also searched (manually) the abstracts of conference proceedings of your American Society of Nephrology from 1998 to 2013. Nevertheless, we didn’t have access to RCTs that have been not reported. Restrictions on language or dates were not imposed in our searches. Ultimately, we discovered 2961 research for the evaluation. Just after screening, 31 studies (on 23 trials) had been included (Fig 1) in the analysis.Study SelectionAll RCTs that studied dialysis ESRD adults (age 18 years) and compared sevelamer to any calcium-based phosphate binder (CBPB) have been integrated.Sorcin/SRI Protein manufacturer Included studies are assumed to possess analyzed the effect of phosphate binders on serum levels of phosphate or calcification of coronary arteries.EGF, Mouse Research comparing sevelamer to any other varieties of phosphate binders or no phosphate binders had been excluded.PMID:36717102 Titles and abstracts were reviewed by two reviewers independently, as well as the full-text articles.PLOS A single | DOI:ten.1371/journal.pone.0133938 July 31,3 /A Meta-Analysis of Sevelamer on DialysisData Extraction and Excellent AssessmentData were extracted by two authors. A third reviewer checked the extracted data for accuracy. The following data had been extracted: country of origin; year of publication; sample size; study design; mean age; percentage of m.
Posted inUncategorized